| Literature DB >> 31587447 |
Ayman Abdelmaksoud1, Aleksandra Vojvodic2, Erhan Ayhan3, Süleyman Dönmezdil4, Tatjana Vlaskovic Jovicevic5, Petar Vojvodic5, Torello Lotti6, Michelangelo Vestita7,8.
Abstract
Isotretinoin (ISO) is a first-generation retinoid discovered in 1952 and approved by the FDA for the treatment of nodulocystic acne in 1982. The anti-inflammatory properties of ISO have found its use in disorders other than acne. ISO can create psychiatric problems, including depression and suicidal ideation. These neuropsychiatric problems are very similar to disorders secondary to hyperhomocysteinemia (HHcy), vitamin B12, and folic acid (vitamin B9) deficiencies. Given that previous literature suggested folate supplementation improved the efficacy of traditional antidepressant medications, clinicians may wish to consider folate supplementation for patients with depression or possible depressive symptoms, such as acne patients with genetic susceptibility. Brain-derived neurotrophic factor may be a cytokine-specific screening biomarker in immune-based antidepressive therapy.Entities:
Keywords: depression; folic acid; low dose isotretinoin
Mesh:
Substances:
Year: 2019 PMID: 31587447 DOI: 10.1111/dth.13104
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 2.851